Literature DB >> 15529342

Anakinra in mutation-negative NOMID/CINCA syndrome: comment on the articles by Hawkins et al and Hoffman and Patel.

Joost Frenkel, Nico M Wulffraat, Wietse Kuis.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15529342     DOI: 10.1002/art.20497

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


× No keyword cloud information.
  15 in total

1.  Anakinra in mutation-negative CINCA syndrome.

Authors:  José Luis Callejas; Javier Oliver; Javier Martín; Norberto Ortego
Journal:  Clin Rheumatol       Date:  2006-01-27       Impact factor: 2.980

2.  Tailoring biological treatment: anakinra treatment of posterior uveitis associated with the CINCA syndrome.

Authors:  S C B Teoh; S Sharma; A Hogan; R Lee; A V Ramanan; A D Dick
Journal:  Br J Ophthalmol       Date:  2007-02       Impact factor: 4.638

Review 3.  Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2007.

Authors:  D E Furst; F C Breedveld; J R Kalden; J S Smolen; G R Burmester; J Sieper; P Emery; E C Keystone; M H Schiff; P Mease; P L C M van Riel; R Fleischmann; M H Weisman; M E Weinblatt
Journal:  Ann Rheum Dis       Date:  2007-11       Impact factor: 19.103

4.  Extreme efficiency of anti-interleukin 1 agent (anakinra) in a Japanese case of CINCA syndrome.

Authors:  Yasuyo Kashiwagi; Hisashi Kawashima; Shigeo Nishimata; Ryuhei Nagao; Kiyoko Watanabe; Kouji Takekuma; Akinori Hoshika
Journal:  Clin Rheumatol       Date:  2007-09-22       Impact factor: 2.980

Review 5.  Autoinflammation: translating mechanism to therapy.

Authors:  Taylor A Doherty; Susannah D Brydges; Hal M Hoffman
Journal:  J Leukoc Biol       Date:  2011-02-17       Impact factor: 4.962

6.  Anakinra: a safe and effective first-line treatment in systemic onset juvenile idiopathic arthritis (SoJIA).

Authors:  C M Hedrich; N Bruck; B Fiebig; M Gahr
Journal:  Rheumatol Int       Date:  2011-11-15       Impact factor: 2.631

7.  Arthropathy of neonatal onset multisystem inflammatory disease (NOMID/CINCA).

Authors:  Suvimol Chirathivat Hill; Madjimbaye Namde; Andrew Dwyer; Andrew Poznanski; Scott Canna; Raphaela Goldbach-Mansky
Journal:  Pediatr Radiol       Date:  2006-11-28

Review 8.  Therapy of autoinflammatory syndromes.

Authors:  Hal M Hoffman
Journal:  J Allergy Clin Immunol       Date:  2009-12       Impact factor: 10.793

9.  Hearing improvement in a patient with variant Muckle-Wells syndrome in response to interleukin 1 receptor antagonism.

Authors:  M Rynne; C Maclean; A Bybee; M F McDermott; P Emery
Journal:  Ann Rheum Dis       Date:  2006-04       Impact factor: 19.103

10.  Critical appraisal of canakinumab in the treatment of adults and children with cryopyrin-associated periodic syndrome (CAPS).

Authors:  Ori Toker; Philip J Hashkes
Journal:  Biologics       Date:  2010-05-25
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.